US2019091192A1PendingUtilityA1
Controlled release pharmaceutical compositions comprising a fumaric acid ester
Est. expiryOct 8, 2024(expired)· nominal 20-yr term from priority
A61P 5/14A61P 37/06A61P 37/00A61P 35/00A61P 7/06A61P 3/10A61P 37/02A61P 43/00A61P 25/04A61P 29/00A61P 19/02A61P 1/16A61P 17/00A61P 1/04A61P 17/06A61P 25/00A61K 9/2077A61K 31/225A61K 9/4808A61K 9/2081A61K 9/2853A61K 9/2027A61K 9/2031A61K 9/2013A61K 9/2866A61K 9/20A61K 31/215A61K 9/2846A61K 9/4891A61K 31/22A61K 9/0053A61K 9/2054A61K 9/50A61K 9/5047A61K 9/48A61K 9/28A61K 9/167A61K 45/06A61K 9/5084A61K 9/5042A61K 9/14A61K 2300/00
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
Claims
exact text as granted — not AI-modified1 .- 45 . (canceled)
46 . A method of reducing a side effect associated with oral treatment with a fumaric acid ester selected from the group consisting of di-(C1-C5)alkylesters of fumaric acid and mono-(C1-C5)alkyl esters of fumaric acid or a pharmaceutically acceptable salt thereof, comprising administering to a patient an NSAID in combination with a controlled release composition comprising one or more fumaric acid ester.
47 . The method of claim 46 , wherein the fumaric acid ester is DMF, MMF or a combination thereof.
48 . The method of claim 47 , wherein the fumaric acid ester is DMF.
49 . The method of claim 47 , wherein the fumaric acid ester is MMF.
50 . The method of claim 46 , wherein the NSAID is aspirin.
51 . The method of claim 47 , wherein the NSAID is aspirin.
52 . The method of claim 48 , wherein the NSAID is aspirin.
53 . The method of claim 49 , wherein the NSAID is aspirin.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.